Our top pick for
Schrödinger, Inc is a health information services business based in the US. Schrödinger shares (SDGR) are listed on the NASDAQ and all prices are listed in US Dollars. Schrödinger employs 392 staff and has a trailing 12-month revenue of around USD$100.9 million.
Since the stock market crash in March caused by coronavirus, Schrödinger's share price has had significant positive movement.
Its last market close was USD$58.79, which is 14.95% up on its pre-crash value of USD$50 and 130.55% up on the lowest point reached during the March crash when the shares fell as low as USD$25.5.
If you had bought USD$1,000 worth of Schrödinger shares at the start of February 2020, those shares would have been worth USD$inf at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$inf.
|Latest market close||USD$58.79|
|52-week range||USD$25.5 - USD$99.5|
|50-day moving average||USD$56.89|
|200-day moving average||USD$65.3025|
|Wall St. target price||USD$83.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.3999|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||20.52%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$100.9 million|
|Gross profit TTM||USD$49.1 million|
|Return on assets TTM||-7.81%|
|Return on equity TTM||-6.04%|
|Market capitalisation||USD$4.8 billion|
TTM: trailing 12 months
There are currently 3.8 million Schrödinger shares held short by investors – that's known as Schrödinger's "short interest". This figure is 0.1% down from 3.8 million last month.
There are a few different ways that this level of interest in shorting Schrödinger shares can be evaluated.
Schrödinger's "short interest ratio" (SIR) is the quantity of Schrödinger shares currently shorted divided by the average quantity of Schrödinger shares traded daily (recently around 1.0 million). Schrödinger's SIR currently stands at 3.72. In other words for every 100,000 Schrödinger shares traded daily on the market, roughly 3720 shares are currently held short.
However Schrödinger's short interest can also be evaluated against the total number of Schrödinger shares, or, against the total number of tradable Schrödinger shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Schrödinger's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Schrödinger shares in existence, roughly 60 shares are currently held short) or 0.127% of the tradable shares (for every 100,000 tradable Schrödinger shares, roughly 127 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Schrödinger.
Find out more about how you can short Schrödinger stock.
We're not expecting Schrödinger to pay a dividend over the next 12 months.
Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.